Search Results
Your search for The ASCO matches 21094 pages
Showing 11751 - 11800FDA Grants Priority Review for Daratumumab in Front-Line Multiple Myeloma Setting
On January 19, the U.S. Food and Drug Administration (FDA) granted Priority Review to the supplemental Biologics License Application (sBLA) for the use of daratumumab (Darzalex) in combination with bortezomib (Velcade), melphalan, and prednisone for the treatment of patients with newly diagnosed...
Fox Chase Announces Winners of ACS Institutional Research Grant for Junior Investigators
Fox Chase Cancer Center and the Lewis Katz School of Medicine are pleased to announce the winners of its American Cancer Society (ACS) Institutional Research Grant Pilot Project Competition for Junior Investigators. The competition was open to eligible junior faculty at Fox Chase Cancer Center and ...
Israel Cancer Research Fund Appoints National Executive Director
Mark A. Israel, MD, a pediatric oncologist, translational scientist, and a recognized leader in cancer research has been appointed National Executive Director of the Israel Cancer Research Fund (ICRF), a nonprofit organization dedicated solely to funding cancer research in Israel. Dr. Israel joins ...
The Telltale Heart: A Surgeon’s Memoir
We don’t feel our liver or pancreas working, but we all feel our hearts beating—the drumbeat of our mortality since we all have a finite number of heartbeats from birth to death. And unlike with most other organs, we are painfully aware of how fragile this mighty muscle can be. About 610,000 people ...
Internationally Renowned Prostate Cancer Expert Gerald E. Hanks, MD, Dies
FROM WILHELM RÖNTGEN’S groundbreaking discovery of x-rays in 1895, the history of radiotherapy has been rich with colorful paradigm-changing researchers and physicians who over the past century have transformed the field into one of the pillars of cancer treatment. One such trailblazer who...
A Neuroscientist Examines Intact Minds Adrift in Damaged Brains and Bodies
Understanding what consciousness is, and why and how it evolved, is perhaps the greatest mystery known to science. With its 100 billion or so neurons and a processing rate of about 4 billion bits per second, the human brain is a miraculously complicated entity, much of which is still under...
Community Oncology Alliance Elects Officers and New Board Members for 2018
THE COMMUNITY ONCOLOGY ALLIANCE (COA) is pleased to announce the election of new members to the Board of Directors and Executive Committee. Additionally, the COA Board has launched and nominated participants for a dedicated standing committee on Government Affairs and Policy as well as Payment...
Against All Odds
The days leading up to our daughter Emily’s diagnosis of acute lymphoblastic leukemia (ALL) on May 28, 2010, when she was just 5, offered few clues about the terrifying, life-and-death months and years we were about to experience. She was happy and seemingly healthy, literally until the day before...
2018 GI CANCERS SYMPOSIUM: Nivolumab Plus Ipilimumab Yields Survival Benefit in Metastatic Colorectal Cancer
Nivolumab (Opdivo) plus ipilimumab (Yervoy) led to a 1-year overall survival rate of 85% in previously treated metastatic colorectal cancer patients with DNA mismatch repair–deficient (dMMR) or microsatellite instability–high (MSI-H) tumors. These data were presented in the first report ...
Working Together to Help Pediatric Patients With Cancer Live and Live Well
While many patients with cancer can benefit from palliative care to ease symptoms from the disease or its treatment, for children with cancer, especially critically ill children, palliative care can provide an additional layer of medical and emotional support for both young patients and their...
Pomegranates and Other Polyphenols: New Evidence to Share With Prostate Cancer Patients
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies commonly used by patients with cancer. In this installment, Channing Paller, MD, explores the role of pomegranate- and grape-based...
FDA Approves Arsenic Trioxide With Tretinoin for First-Line Treatment of Acute Promyelocytic Leukemia
ON JANUARY 15, 2018, the U.S. Food and Drug Administration (FDA) approved the use of arsenic trioxide (Trisenox) injection in combination with tretinoin for the treatment of adults with newly diagnosed low-risk acute promyelocytic leukemia whose disease is characterized by the presence of the...
FDA Approves Olaparib for Germline BRCA-Mutated Metastatic Breast Cancer
On January 12, 2018, the U.S. Food and Drug Administration (FDA) granted regular approval to olaparib (Lynparza), a poly ADP-ribose polymerase (PARP) inhibitor, for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative metastatic breast cancer who...
FDA Approves Afatinib for Previously Untreated, Metastatic NSCLC With Other Nonresistant EGFR Mutations
On January 12, 2018, the U.S. Food and Drug Administration (FDA) granted approval to afatinib (Gilotrif) for a broadened indication in first-line treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors have nonresistant epidermal growth factor receptor (EGFR) mutations ...
2018 GI CANCERS SYMPOSIUM: First-Line Lenvatinib vs Sorafenib in Unresectable Hepatocellular Carcinoma
The results of an analysis of the phase III REFLECT trial of lenvatinib mesylate (Lenvima) vs sorafenib (Nexavar) as first-line treatment for unresectable hepatocellular carcinoma based on independent imaging review were presented during the 2018 Gastrointestinal (GI) Cancers Symposium (Abstract...
Durvalumab Takes a Giant Leap Into Stage III NSCLC
Immune checkpoint inhibitors have had a dramatic impact on survival for patients with stage IV non–small cell lung cancer (NSCLC), with whispers that a cure might be achieved in a subset of patients. In typical fashion, active new agents are evaluated in earlier stages of disease. Stage III NSCLC...
Levine Cancer Institute Creates Integrated Department of Supportive Oncology to Be Led by Declan Walsh, MD
Levine Cancer Institute (LCI) has announced a new Department of Supportive Oncology, helmed by palliative medicine pioneer Declan Walsh, MD. Under the leadership of Dr. Walsh, the new department will integrate its services throughout the Institute. The department includes cancer rehabilitation,...
2018 GI CANCERS SYMPOSIUM: Nab-Paclitaxel Plus Gemcitabine in Locally Advanced Pancreatic Cancer
Primary endpoint findings and updated results of secondary endpoints from the phase II LAPACT trial of nanoparticle albumin–bound (nab)-paclitaxel (Abraxane) plus gemcitabine in patients with locally advanced pancreatic cancer were presented by Hammel et al at the 2018 Gastrointestinal (GI)...
2018 GI CANCERS SYMPOSIUM: Novel Triplet Combination Improves Progression-Free Survival in Patients With BRAF-Mutant Colorectal Cancer
Updated results were recently reported from the 30 patient safety lead-in of the phase III BEACON CRC trial evaluating the triplet combination of encorafenib (a BRAF inhibitor), binimetinib (an MEK inhibitor), and cetuximab (Erbitux, an anti–EGFR antibody) in patients with BRAF-mutant...
Ursula Matulonis, MD, Named Brock-Wilson Family Chair at Dana-Farber Cancer Institute
Ursula Matulonis, MD, has been named the first incumbent of the Brock-Wilson Family Chair at Dana-Farber Cancer Institute (Dana-Farber). The newly established Chair was created to advance gynecologic oncology research and support a highly dedicated faculty member at Dana-Farber. Dr. Matulonis is...
Mary Beckerle, PhD, Honored by National Cancer Institute
Mary Beckerle, PhD, Chief Executive -Officer and Director of Huntsman Cancer Institute at the University of Utah, is this year’s recipient of the Alfred G. Knudson Award in Cancer Genetics from the National Cancer Institute (NCI). The prestigious award is named after Alfred G. Knudson, MD, PhD, a...
ASCO Endorsement of ASTRO Guideline on Stereotactic Body Radiotherapy for NSCLC Highlights Shared Patient Decision-Making
As reviewed in this issue of The ASCO Post, a recent ASCO panel, chaired by Bryan Schneider, MD, and Brendon Stiles, MD, has provided an endorsement of a recently published guideline on the use of stereotactic body radiotherapy for non–small cell lung cancer.1 The original guideline,2 developed and ...
ASCO Endorses ASTRO Guideline on Stereotactic Body Radiotherapy for Early-Stage NSCLC
As reported in the Journal of Clinical Oncology by Bryan J. Schneider, MD, of the University of Michigan, Ann Arbor, and colleagues, ASCO has endorsed the recently released American Society for Radiation Oncology (ASTRO) evidence-based guideline on stereotactic body radiotherapy (SBRT) in early...
Ramesh K. Ramanathan, MD, on Metastatic Pancreatic Cancer: Results From a SWOG Study
Ramesh K. Ramanathan, MD, of the Mayo Clinic, discusses early-phase study findings on mFOLFIRINOX (mFFOX) plus pegylated recombinant human hyaluronidase vs mFFOX alone in patients with a good performance status (Abstract 208).
Diary of a Storm
FOR DAYS BEFORE HURRICANE HARVEY was expected to move toward Houston, Texas, on Sunday, August 27, 2017, after pummeling other cities in Texas and Louisiana, the leadership team at The University of Texas MD Anderson Cancer Center (MD Anderson) in Houston strategized on how to ensure the...
Erratum
In the December 25 issue of The ASCO Post, a photo published for Eduardo Oliveira, PhD, was incorrect. The correct photo is printed here. Dr. Oliveira is Professor of Exercise Physiology and Exercise Cancer Specialist at Mama Help Breast Cancer Support Center at the University of Porto, in Lisbon, ...
Roswell Park Cancer Institute Appoints New Leaders for 2018
AT THE START OF 2018, seven senior employees assumed new roles at Roswell Park Cancer Institute in Buffalo, New York. Five of these program leaders were promoted or reappointed, and two have newly joined the Institute from other centers around the United States. Meet the Appointees Charles...
Cancer Statistics, 2018: U.S. Cancer Mortality Continues Decades-Long Drop
THE CANCER death rate dropped 1.7% from 2014 to 2015, continuing a drop that began in 1991 and has reached 26%, resulting in nearly 2.4 million fewer cancer deaths during that time. The data are reported in “Cancer Statistics, 2018,” the American Cancer Society’s comprehensive annual report on...
Listen to Conquer Cancer Mini-Podcasts Inspired by StoryCorps and ASCO Members, Grantees
Debuting this year, “Your Stories: Conquering Cancer” are unscripted conversations among doctors, patients, and caregivers who have been affected by cancer. The Conquer Cancer Foundation produced the mini-podcast series through the award-winning StoryCorps organization, a national nonprofit...
Now Available: Limited Edition Conquer Cancer Foundation Nike Sneakers
PURCHASE A pair of limited edition ASCO’s Conquer Cancer Foundation Nike Roshe LD-1000 sneakers, available exclusively from Conquer Cancer. The sneakers celebrate 15.5 million cancer survivors across the United States and are a great way to start the new year on the right foot! Sizes are limited;...
CancerLinQ® Partners With Leading Global Life Sciences Nonprofit
CANCERLINQ LLC and DIA (Drug Information Association), a global nonprofit association of health-care product development professionals, recently announced that they have entered into a programmatic partnership. Under the agreement, DIA will offer the scientific expertise of its members from the...
ASCO Calls for Streamlining of Adverse Events Reporting for Cancer Clinical Trials
ASCO HAS released recommendations to streamline serious adverse events reporting for cancer clinical trials. The ASCO research statement, published last month in the Journal of Clinical Oncology (JCO), discusses strategies to address the high volume of uninformative adverse events reports submitted ...
Educate and Support Your Patients With ASCO Answers Materials
GIVE YOUR PATIENTS ASCO-approved information on diagnosis, treatment, side effects, and the psychosocial impact of cancer. Cancer.Net is ASCO’s patient information website, and it offers fact sheets and comprehensive, patient-friendly ASCO Answers guides. These easy-to-read materials cover breast, ...
2018 ASCO Annual Meeting Call for Abstracts: Submit by February 13
ASCO INVITES you to submit an abstract for the 2018 ASCO Annual Meeting. Submit an abstract by February 13, 2018, at 11:59 PM (EST) to be considered for presentation or publication at this year’s Annual Meeting, to be held June 1–5 in Chicago, Illinois. The 2017 ASCO Annual Meeting attracted...
Howard A. ‘Skip’ Burris III, MD, FACP, FASCO, Elected ASCO President for 2019–2020 Term
Howard A. “Skip” Burris III, MD, FACP, FASCO, a long-time member and volunteer, has been elected to serve as the President of ASCO for the term beginning in June 2019. He will take office as President-Elect during the ASCO Annual Meeting in Chicago in June 2018. Additionally, five members were...
Chi Van Dang, MD, PhD, Named Editor-in-Chief of Cancer Research
THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) is pleased to announce the appointment of Chi Van Dang, MD, PhD, as Editor-in-Chief of its Cancer Research journal. Published under different titles in its early years, Cancer Research was the first English-language journal to be published in the ...
Laura Levin, MD, Joins Fox Chase Cancer Center Department of Diagnostic Imaging
FOX CHASE CANCER CENTER is pleased to welcome Board-certified radiologist Laura Levin, MD, as Assistant Professor in the Department of Diagnostic Imaging. Dr. Levin assumed her new position on January 2, 2018. Dr. Levin comes to Fox Chase Cancer Center from a high-volume private practice in which ...
Mark Saunders, MD, PhD, on Colorectal Cancer: Results From the SCOT Trial
Mark Saunders, MD, PhD, of Christie Hospital, discusses study findings on tumor sidedness and the influence of chemotherapy duration on disease-free survival (Abstract 558).
Andrew X. Zhu, MD, PhD, on HCC: Results From KEYNOTE-224
Andrew X. Zhu, MD, PhD, of Massachusetts General Hospital, discusses study findings on pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (Abstract 209).
Thierry André, MD, and Michael J. Overman, MD, on Colorectal Cancer: Results From Two CheckMate-142 Trials
Thierry André, MD, of Hôpital Saint-Antoine, and Michael J. Overman, MD, of The University of Texas MD Anderson Cancer Center, discuss findings from their respective CheckMate-142 studies on nivolumab and ipilimumab in patients with DNA mismatch repair–deficient/microsatellite instability–high...
Abraham J. Wu, MD, on Esophageal Cancer: Impact of Lung and Heart Dose on Survival After Radiotherapy
Abraham J. Wu, MD, of Memorial Sloan Kettering Cancer Center, discusses his findings that suggest efforts to reduce lung dose, such as shrinking the treatment volumes or using proton therapy, may improve outcomes in esophageal cancer (Abstract 3).
Maria Svensson, MD, PhD Candidate, on Esophageal and Gastric Cancers: Significance of PD-1 and PD-L1 Expression
Maria Svensson, MD, PhD Candidate, of Lund University, discusses high expression of PD-1 and PD-L1 in chemotherapy-naive esophageal and gastric adenocarcinomas, the implications for survival, and the link to a deficiency in mismatched repair genes (Abstract 9).
Pieter van der Sluis, MD, PhD, on Esophageal Cancer: Results From a Surgical Treatment Trial
Pieter van der Sluis, MD, PhD, of the University Medical Center Utrecht, discusses study findings that compared robot-assisted minimally invasive thoracolaparoscopic esophagectomy vs open transthoracic esophagectomy for resectable esophageal cancer (Abstract 6).
Manish A. Shah, MD, on Gastric Cancer: Results From the RAINFALL Trial
Manish A. Shah, MD, of Weill Cornell Medicine, discusses phase III study findings on cisplatin plus capecitabine or fluorouracil with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophageal junction adenocarcinoma (Abstract 5).
Florian Lordick, MD, on Gastric Cancer: Final Results From the AIO Trial
Florian Lordick, MD, of the University Medicine Leipzig, discusses study findings on intraperitoneal immunotherapy with the antibody catumaxomab for patients with peritoneal carcinomatosis from gastric cancer (Abstract 4).
Steven D. Leach, MD, on Pancreatic Cancer: Keynote Lecture
Steven D. Leach, MD, of Dartmouth University’s Norris Cotton Cancer Center, discusses the personalized approach that GI cancers will require to make rational use of immunotherapy—including a subset of pancreatic cancers, which appear to be highly immunogenic and are associated with long-term...
David H. Ilson, MD, PhD, on Improving Esophageal Cancer Outcomes: Future Directions
David H. Ilson, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the merits of preoperative chemotherapy vs chemoradiotherapy, the role of targeted agents, recent results from genomic profiling, and whether PET scans can guide neoadjuvant treatment.
Basem Azab, MD, on Esophageal Cancer: Study Survival Results
Basem Azab, MD, of the Sylvester Comprehensive Cancer Center, University of Miami, discusses the impact on overall survival when more than 2 months elapse between finishing neoadjuvant therapy and undergoing esophagectomy (Abstract 2).
Kyaw L. Aung, MBBS, PhD, on Pancreatic Cancer: Results From the COMPASS Trial
Kyaw L. Aung, MBBS, PhD, of Princess Margaret Cancer Centre, discusses early study findings on genomics-driven precision medicine for advanced pancreatic ductal carcinoma (Abstract 211).
Khaldoun Almhanna, MD, MPH, on Gastric Cancer: Results From the CCOG 1102 Trial
Khaldoun Almhanna, MD, MPH, of the H. Lee Moffitt Cancer Center, discusses the long-term outcome of a phase III study that explored the significance of extensive intraoperative peritoneal lavage in addition to standard treatment for ≥ T3 resectable gastric cancer (Abstract 1).
